CNA-loaded PLGA nanoparticles improve humoral response againstS. aureus-mediated infections in a mouse model: subcutaneous vs. nasal administration strategy

References

• Alpar HO, Papanicolaou I, Bramwell VW. Strategies for DNA vaccine delivery. Expert Opin Drug Deliv, 2005;2(5):829–42.
   PubMedGoogle Scholar
• Audran R, Peter K, Dannull J, Men Y, Scandella E, Groettrup M, Gander B, Corradin G. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine, 2003;21:1250–5.
   PubMed Web of Science ®Google Scholar
• Ballester M, Nembrini C, Dhar N, de Titta A, de Piano C, Pasquier M, Simeoni E, van der Vlies AJ, McKinney JD, Hubbell JA. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine, 2011;29(40):6959–66.
   PubMed Web of Science ®Google Scholar
• Berger J, Reist M, Mayer JM, Felt O, Gurny R. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur J Pharm Biopharm, 2004;57(1):35–52.
   PubMed Web of Science ®Google Scholar
• Bramwell VW, Eyles JE, Alpar HO. Particulate delivery systems for biodefense subunit vaccines. Adv Drug Deliv Rev, 2005;57(9):1247–65.
   PubMed Web of Science ®Google Scholar
• Brito LA, Malyala P, O’Hagan DT. Vaccine adjuvant formulations: A pharmaceutical perspective. Semin Immunol, 2013;25:130–45.
   PubMed Web of Science ®Google Scholar
• Cevher E, Salomon SK, Makrakis A, Li XW, Brocchini S, Alpar HO. Development of chitosan–pullulan composite nanoparticles for nasal delivery of vaccines: Optimisation and cellular studies. J Microencaps, 2015;32(8):755–68.
   PubMed Web of Science ®Google Scholar
• Chenite A, Buschmann M, Wang D, Chaput C, Kandani N. Rheological characterisation of thermogelling chitosan/glycerol-phosphate solutions. Carbohydrate Pol, 2001;46(1):39–47.
   Web of Science ®Google Scholar
• Cho J, Heuzey MC, Bégin A, Carreau PJ. Physical gelation of chitosan in the presence of beta-glycerophosphate: The effect of temperature. Biomacromolecules, 2005;6(6):3267–75.
   PubMed Web of Science ®Google Scholar
• Colonna C, Dorati D, Conti B, Caliceti P, Genta I. Sub-unit vaccine against S. aureus-mediated infections: Set-up of nano-sized polymeric adjuvant. Int J Pharm, 2013;452:390–401.
   PubMed Web of Science ®Google Scholar
• Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev, 2009;61:140–57.
   PubMed Web of Science ®Google Scholar
• Diederen BMW, Kluytmans JAJW. The emergence of infections with community-associated methicillin resistant Staphylococcus aureus. J Infect, 2006;52(3):157–68.
   PubMed Web of Science ®Google Scholar
• Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, Lin F, Lin J, Carleton HA, Mongodin EF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin resistant S. aureus. Lancet, 2006;367:731–9.
   PubMed Web of Science ®Google Scholar
• Fievez V, Plapied L, des Rieux A, Pourcelle V, Freichels H, Wascotte V, Vanderhaeghen ML, Jerôme C, Vanderplasschen A, Marchand-Brynaert J, et al. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur J Pharm Biopharm, 2009;73(1):16–24.
   PubMed Web of Science ®Google Scholar
• Fortuna A, Alves G, Serralheiro A, Sousa J, Falcao A. Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules. Eur J Pharm Biopharm, 2014;88(1):8–27.
   PubMed Web of Science ®Google Scholar
• Joshi DP, Lan-Chun-Fung YL, Pritchard JW. Determination of poly(vinyl alcohol) via its complex with boric acid and iodine. Anal Chim Acta, 1979;104:153–60.
   Web of Science ®Google Scholar
• Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol, 2012;61:927–34.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Mauler R, Gruschkau H, Speiser PP. The use of new polymethylmethacrylate adjuvants for split influenza vaccines. Exp Cell Biol, 1976;44:12–19.
   PubMedGoogle Scholar
• Lee PW, Hsu SH, Tsai JS, Chen FR, Huang PJ, Ke CJ, Liao ZX, Hsiao CW, Lin HJ, Sung HW. Multifunctional core-shell polymeric nanoparticles for transdermal DNA delivery and epidermal Langerhans cells tracking. Biomaterials, 2010;31:2425–34.
   PubMed Web of Science ®Google Scholar
• Lindblad EB. Aluminium adjuvants-in retrospect and prospect. Vaccine, 2004;22:3658–68.
   PubMed Web of Science ®Google Scholar
• Look M, Bandyopadhyay A, Blum JS, Fahmy TM. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev, 2010;62:378–93.
   PubMed Web of Science ®Google Scholar
• Lowy FD. Staphylococcus aureus infections. N Engl J Med, 1998;333:520–32.
   Web of Science ®Google Scholar
• Mallapragada SK, Narasimhan B. Immunomodulatory biomaterials. Int J Pharm, 2008;364:235–71.
   Web of Science ®Google Scholar
• Mamo T, Poland GA. Nanovaccinology: The next generation of vaccines meets 21st century materials science and engineering. Vaccine, 2012;30:6609–11.
   PubMed Web of Science ®Google Scholar
• Manish M, Rahi A, Kaur M, Bhatnagar R, Singh S. A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge. PLoS ONE, 2013;8:e61885–90.
   PubMed Web of Science ®Google Scholar
• McCullough KC, Summerfield A. Targeting the porcine immune system-particulate vaccines in the 21st century. Dev Comp Immunol, 2009;33:394–409.
   PubMed Web of Science ®Google Scholar
• Meeusen EN. Exploiting mucosal surfaces for the development of mucosal vaccines. Vaccine, 2011;29:8506–11.
   PubMed Web of Science ®Google Scholar
• Montanaro L, Speziale P, Campoccia D, Ravaioli S, Cangimi I, Pietrocola G, Giannini S, Arciola CR. Scenery of Staphylococcus implant infections in orthopedics. Future Microbiol, 2011;6(11):1329–49.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant: ‘The long and winding road’. Drug Disc, 2009;14(11/12):541–51.
   Google Scholar
• O’Hagan DT, Rahman D, McGee JP, Jeffery H, Davies MC, Williams P, Davis SS, Challacombe SJ. Biodegradable microparticles as controlled release antigen delivery systems. Immunology, 1991;73:239–42.
   PubMed Web of Science ®Google Scholar
• Otto M. Targeted immunotherapy for Staphylococcal infections: Focus on anti-MSCRAMM antibodies. Biodrugs, 2008;22(1):27–36.
   PubMed Web of Science ®Google Scholar
• Patti MJ, Jonsson H, Guss B, Switalski LM, Wiberg K, Lindberg M, Hook M. Molecular characterization and expression of a gene encoding a Staphylococcus aureus collagen adhesin. J Biol Chem, 1992;267(7):4766–72.
   PubMed Web of Science ®Google Scholar
• Pavot V, Rochereau N, Genin C, Verrier B, Paul S. New insights in mucosal vaccine development. Vaccine, 2012;30:142–54.
   PubMed Web of Science ®Google Scholar
• Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Del Rev, 2008;60:915–28.
   PubMed Web of Science ®Google Scholar
• Ravi Kumar MNV. A review of chitin and chitosan applications. React Functional Pol, 2000;46:1–27.
   Web of Science ®Google Scholar
• Rivas JM, Speziale P, Patti JM, Hook M. MSCRAMM: Targeted vaccines and immunotherapy for staphylococcal infection. Curr Opin Drug Disc Dev, 2004;7(2):223–7.
   PubMedGoogle Scholar
• Sharp FA, Ruane D, Claassa B, Creagh E, Harris J, Malyala P, Singh M, O'Hagan DT, Pétrilli V, Tschopp J, et al. Uptake of particulate vaccine adjuvants by dendritic cellsactivates the NALP3 inflammasome. Proc Natl Acad Sci USA, 2009;106:870–5.
   PubMed Web of Science ®Google Scholar
• Silva AL, Rosalia RA, Sazak A, Carstens MG, Ossendorp S, Oostendorp J, Jiskoot W. Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: lw burst-release is crucial for efficient CD8(+)T cell activation. Eur J Pharm Biopharm, 2013;83:338–45.
   PubMed Web of Science ®Google Scholar
• Sun HF, Pollock GJ, Brewer JM. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine, 2003;21:849–55.
   PubMed Web of Science ®Google Scholar
• Vidard L, Kovacsovics-Bankowski M, Kraeft SK, Chen LB, Benacerraf B, Rock KL. Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol, 1996;156:2809–18.
   PubMed Web of Science ®Google Scholar
• Visai L, Xu Y, Casolini F, Rindi S, Hook M, Speziale P. Monoclonal antibodies to CNA, a collagen-binding microbial surface component recognizing adhesive matrix molecules, detach Staphylococcus aureus from a Collagen substrate. J Biol Chem, 2000;275(51):39837–45.
   PubMed Web of Science ®Google Scholar
• Wendorf J, Singh M, Chesko J, Kazzaz J, Soewanan E, Ugozzoli M, O'Hagan D. A practical approach to the use of nanoparticles for vaccine delivery. J Pharm Sci, 2006;95:2738–50.
   PubMed Web of Science ®Google Scholar
• Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg APJ. Nanoparticle vaccines. Vaccine, 2014;32:327–37.
   PubMed Web of Science ®Google Scholar